Javier San - Apr 15, 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Mark Worthington, Attorney-in-Fact for Javier San Martin
Stock symbol
ATHA
Transactions as of
Apr 15, 2024
Transactions value $
$0
Form type
4
Date filed
4/16/2024, 04:37 PM
Previous filing
Jan 8, 2024
Next filing
Oct 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +400K $0.00 400K Apr 15, 2024 Common Stock 400K $2.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option will vest on the one (1) year anniversary of the date of grant, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2024 Inducement Equity Incentive Plan) through the applicable vesting dates.